What is the share price of Kwality Pharmaceuticals Ltd (KPL) today?
The share price of KPL as on 24th July 2026 is ₹2781.70. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Kwality Pharmaceuticals Ltd (KPL) share?
The past returns of Kwality Pharmaceuticals Ltd (KPL) share are- Past 1 week: -0.16%
- Past 1 month: 14.71%
- Past 3 months: 71.55%
- Past 6 months: 164.09%
- Past 1 year: 133.12%
- Past 3 years: 750.67%
- Past 5 years: 1214.29%
What are the peers or stocks similar to Kwality Pharmaceuticals Ltd (KPL)?
The peers or stocks similar to Kwality Pharmaceuticals Ltd (KPL) include:What is the market cap of Kwality Pharmaceuticals Ltd (KPL) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kwality Pharmaceuticals Ltd (KPL) is ₹2886.35 Cr as of 24th July 2026.What is the 52 week high and low of Kwality Pharmaceuticals Ltd (KPL) share?
The 52-week high of Kwality Pharmaceuticals Ltd (KPL) is ₹2890.30 and the 52-week low is ₹828.80.What is the PE and PB ratio of Kwality Pharmaceuticals Ltd (KPL) stock?
The P/E (price-to-earnings) ratio of Kwality Pharmaceuticals Ltd (KPL) is 42.86. The P/B (price-to-book) ratio is 11.00.Which sector does Kwality Pharmaceuticals Ltd (KPL) belong to?
Kwality Pharmaceuticals Ltd (KPL) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Kwality Pharmaceuticals Ltd (KPL) shares?
You can directly buy Kwality Pharmaceuticals Ltd (KPL) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Kwality Pharmaceuticals Ltd
KPL Share Price
NSE₹2,781.704.09% (+109.40)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
KPL Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
KPL Performance & Key Metrics
KPL Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 42.84 | 11.00 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 44.74 | 5.90 | 0.53% |
KPL Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
KPL Company Profile
Kwality Pharmaceuticals Limited manufactures and exports pharmaceutical formulations for human and veterinary use.
SUNPHARMA
PE Ratio
40.57
40.57
1Y Return
14.72%
14.72%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
87.23
87.23
1Y Return
40.96%
40.96%
Buy Reco %
78.57
78.57
CIPLA
PE Ratio
29.38
29.38
1Y Return
5.20%
5.20%
Buy Reco %
66.67
66.67
ZYDUSLIFE
PE Ratio
21.94
21.94
1Y Return
14.15%
14.15%
Buy Reco %
55.17
55.17
LUPIN
PE Ratio
20.32
20.32
1Y Return
22.10%
22.10%
Buy Reco %
55.56
55.56
KPL Sentiment Analysis
KPL Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
KPL Stock Summary · May 2026
Strong results and a clear growth-first agenda: management reported FY26 revenue of INR503 crore (≈+36% YoY) and PAT of INR67 crore (+69%), and used the quarter to outline conservative yet ambitious FY27–29 milestones. They emphasized margin expansion through a shift into higher‑regulated products and scale, citing target EBITDA of roughly 26–27% at INR650 crore, ~28% at INR800–850 crore and ~30% by INR1,000 crore, alongside a recent ICRA upgrade to BBB+. Execution priorities were capacity build‑out in oncology (a ~INR50 crore expansion to lift utilization and drive INR150–300 crore in oncology sales through FY29), Unit 6 hormones capex (total ~INR65 crore, WHO GMP target by November and treated as upside to the INR1,000 crore baseline), biosimilar and BE program ramps, and a broad ~INR260–270 crore capex plan funded largely from working capital and operating cash. Management acknowledged near‑term working‑capital pressure from delayed receivables but said collections are improving, guided FY27 revenue at INR650–700 crore with quarterly pacing (Q1 ~INR150–160 crore) and expects ~15–20% sequential growth through FY27.
KPL Stock Growth Drivers
KPL Stock Growth Drivers
7Record FY26 financial performance and profitability uplift
Kwality delivered its highest-ever quarterly and annual revenues in FY26, with Q4 revenue rising 35.8%
Operational and compliance validation (audits, ratings and governance steps)
Operational quality and compliance have been strengthened and externally validated: the company cleared multiple international
KPL Stock Challenges
KPL Stock Challenges
5Working-capital strain from concentrated export receivables
Receivables rose materially (cited at roughly INR130 crore) after large, concentrated sales into Algeria and
Sustained margin compression driven by input-cost inflation and poor price pass-through
Gross margins have trended down from the mid-50% range to the high-40s over the past
KPL Forecast
KPL Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
KPL
KPL
Income
Balance Sheet
Cash Flow
Quarterly Normal View
KPL Income Statement
KPL Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 78.71 | 92.56 | 80.36 | 90.26 | 85.06 | 116.44 | 111.85 | 111.95 | 123.97 | 158.17 | ||||||||||
Operating & Other expenses | 61.41 | 78.45 | 62.74 | 70.37 | 66.91 | 89.79 | 87.30 | 85.70 | 94.32 | 118.35 | ||||||||||
EBITDA | 17.30 | 14.11 | 17.62 | 19.89 | 18.15 | 26.65 | 24.55 | 26.25 | 29.65 | 39.82 | ||||||||||
| Depreciation/Amortization | 4.82 | 5.07 | 4.03 | 4.62 | 4.56 | 5.09 | 4.76 | 4.96 | 4.82 | 5.26 | ||||||||||
| PBIT | 12.48 | 9.04 | 13.59 | 15.27 | 13.59 | 21.56 | 19.79 | 21.29 | 24.83 | 34.56 | ||||||||||
| Interest & Other Items | 2.73 | 3.06 | 2.48 | 2.71 | 2.20 | 2.49 | 2.76 | 2.84 | 2.48 | 2.89 | ||||||||||
| PBT | 9.75 | 5.98 | 11.11 | 12.56 | 11.39 | 19.07 | 17.03 | 18.45 | 22.35 | 31.67 | ||||||||||
| Taxes & Other Items | 2.06 | 1.62 | 2.76 | 4.09 | 2.86 | 4.58 | 5.10 | 4.33 | 6.34 | 6.36 | ||||||||||
| Net Income | 7.69 | 4.36 | 8.35 | 8.47 | 8.53 | 14.49 | 11.93 | 14.12 | 16.01 | 25.31 | ||||||||||
| EPS | 7.39 | 4.08 | 8.04 | 8.15 | 8.21 | 13.95 | 11.49 | 13.60 | 15.42 | 24.39 |
KPL Company Updates
KPL Stock Peers
KPL Past Performance & Peer Comparison
KPL Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Kwality Pharmaceuticals Ltd | 42.86 | 11.00 | — |
| Sun Pharmaceutical Industries Ltd | 40.57 | 5.55 | 0.82% |
| Torrent Pharmaceuticals Ltd | 87.23 | 10.73 | 0.68% |
| Cipla Ltd | 29.38 | 3.30 | 0.92% |
KPL Stock Price Comparison
Compare KPL with any stock or ETFCompare KPL with any stock or ETF
KPL
KPL Holdings
KPL Shareholdings
KPL Promoter Holdings Trend
KPL Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
KPL Institutional Holdings Trend
KPL Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
KPL Shareholding Pattern
KPL Shareholding Pattern
KPL Shareholding History
KPL Shareholding History
Foreign Institutions
Mutual Funds Invested in KPL
Mutual Funds Invested in KPL
No mutual funds holding trends are available
Top 1 Mutual Funds holding Kwality Pharmaceuticals Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0000% | Percentage of the fund’s portfolio invested in the stock 0.08% | Change in the portfolio weight of the stock over the last 3 months 0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 0/130 (0) |
Compare 3-month MF holding change on Screener
smallcases containing KPL stock
smallcases containing KPL stock
Looks like this stock is not in any smallcase yet.
KPL Events
KPL Events
KPL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
KPL has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
KPL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
KPL has not given any dividends in last 5 years
KPL Upcoming Dividends
KPL Upcoming Dividends
No upcoming dividends are available
KPL Past Dividends
KPL Past Dividends
Cash Dividend
Ex DateEx DateJan 5, 2017
Interim
Interim | Div/Share: ₹0.60
Dividend/Share
₹0.60
Ex DateEx Date
Jan 5, 2017
KPL Stock News & Opinions
KPL Stock News & Opinions
Articles & Videos
Corporate
Corporate
Kwality Pharmaceuticals receives CDSCO approval to manufacture Pembroluzimab for preclinical studiesKwality Pharmaceuticals has achieved a significant milestone in its biologics development journey after receiving permission from the Central Drugs Standard Control Organization (CDSCO) to manufacture pilot batches of Pembroluzimab for preclinical studies. The approval follows a comprehensive review of the product's development data submitted by the Company's R&D team. Based on the data evaluated, CDSCO has granted permission to proceed with pilot-scale manufacturing for the generation of preclinical batches, marking the product's transition from the research and development stage to Pre-Clinical stage.
1 day agoCapital Market - Live
Spotlight
Spotlight
Kwality Pharma surges on strong Q4 numbers; PAT jumps 75%The company's consolidated net profit surged 74.60% to Rs 25.30 crore in Q4 FY26, compared with Rs 14.49 crore in the same period last year. Revenue from operations rose 35.81% YoY to Rs 157.11 crore in the quarter ended 31 March 2026. On a sequential basis, net profit increased 58.02% and revenue grew 27.27% over Q3 FY26. Profit before tax stood at Rs 31.67 crore in Q4 FY26, up 66.07% year-on-year and up 36.68% quarter-on-quarter. EBITDA jumped 50.38% to Rs 38.8 crore in the March quarter, compared with Rs 25.8 crore a year earlier. EBITDA margin improved to 24.6% from 22% in the corresponding period last year. For the full financial year FY26, the company reported a 69% surge in consolidated net profit to Rs 67.35 crore, while revenue from operations rose 35.89% to Rs 503.08 crore. Kwality Pharmaceuticals is engaged in the business of manufacturing & trading in pharmaceuticals & allied products. Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Earnings
Kwality Pharmaceuticals consolidated net profit rises 74.60% in the March 2026 quarterNet profit of Kwality Pharmaceuticals rose 74.60% to Rs 25.30 crore in the quarter ended March 2026 as against Rs 14.49 crore during the previous quarter ended March 2025. Sales rose 35.81% to Rs 157.11 crore in the quarter ended March 2026 as against Rs 115.68 crore during the previous quarter ended March 2025. For the full year,net profit rose 69.01% to Rs 67.35 crore in the year ended March 2026 as against Rs 39.85 crore during the previous year ended March 2025. Sales rose 35.89% to Rs 503.08 crore in the year ended March 2026 as against Rs 370.20 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales157.11115.68 36 503.08370.20 36 OPM %24.6722.37 -23.5021.72 - PBDT36.9324.16 53 110.1372.43 52 PBT31.6719.07 66 90.3254.14 67 NP25.3014.49 75 67.3539.85 69 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Corporate
Kwality Pharmaceuticals to conduct board meetingKwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 19 May 2026.
2 months agoCapital Market - Live
Corporate
Corporate
Kwality Pharmaceuticals receives upgrade in credit ratings from ICRAKwality Pharmaceuticals has received upgrade in credit ratings for bank loan facilities of the company at ICRA BBB+; Stable / ICRA A2. Further, the ratings have been removed from the 'Issuer Not Cooperating' category.
2 months agoCapital Market - Live
Earnings
Earnings
Kwality Pharmaceuticals consolidated net profit rises 87.69% in the December 2025 quarterNet profit of Kwality Pharmaceuticals rose 87.69% to Rs 16.01 crore in the quarter ended December 2025 as against Rs 8.53 crore during the previous quarter ended December 2024. Sales rose 46.24% to Rs 123.44 crore in the quarter ended December 2025 as against Rs 84.41 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales123.4484.41 46 OPM %24.2620.73 - PBDT28.0015.95 76 PBT23.1811.39 104 NP16.018.53 88 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Corporate
Kwality Pharmaceuticals to announce Quarterly ResultKwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Earnings
Kwality Pharmaceuticals consolidated net profit rises 66.71% in the September 2025 quarterNet profit of Kwality Pharmaceuticals rose 66.71% to Rs 14.12 crore in the quarter ended September 2025 as against Rs 8.47 crore during the previous quarter ended September 2024. Sales rose 23.35% to Rs 111.05 crore in the quarter ended September 2025 as against Rs 90.03 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales111.0590.03 23 OPM %22.8321.84 - PBDT23.4117.18 36 PBT18.4512.55 47 NP14.128.47 67 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Corporate
Kwality Pharmaceuticals to table resultsKwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Corporate
Kwality Pharmaceuticals to conduct AGMKwality Pharmaceuticals announced that the Annual General Meeting(AGM) of the company will be held on 9 September 2025.Powered by Capital Market - Live
11 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 13.93%, vs industry avg of 12.48%
Over the last 5 years, market share increased from 0.09% to 0.1%
Over the last 5 years, net income has grown at a yearly rate of 34.75%, vs industry avg of 10.55%